Ghanshani S, Chen C, Lin B, et al. - Researchers performed this retrospective cohort study to determine the the degree to which treatment with triptans is related to acute myocardial infarction, heart failure, and death. This investigation was carried out within an integrated healthcare delivery system in Southern California. One hundred eighty-nine thousand six hundred eighty-four patients age ≥ 18 years were diagnosed with migraine from January 2009 to December 2018. One hundred thirty thousand six hundred fifty-six were exposed to triptans in this group. By using a propensity score, patients treated with triptans were matched 1:1 to those not exposed to triptans. The incidence rate of acute myocardial infarction was 0.67 per 1,000 person‐year for triptan‐exposed patients vs 1.44 per 1,000 person‐year for non-exposed patients. There was no correlation between triptans exposure and an increased risk of cardiovascular events. Such data provide reassurance about the cardiovascular safety of the use of triptans to treat migraine headaches medically.